Moteur de recherche d’entreprises européennes
Financement de l’UE (3 627 681 €) : L’allostérie dans la découverte de médicaments Hor04/06/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
L’allostérie dans la découverte de médicaments
Most current drugs are designed to bind directly to the primary active sites (also known as orthosteric sites) of their biological targets. Allosteric modulators offer a powerful yet underexploited therapeutic approach. They can elicit a richer variety of biological responses and, since they target less conserved binding sites, higher selectivity and less adverse effects may be obtained (Changeux, Drug Disc Today 2013). This proposal aims to train a new generation of scientists in exploiting the concept of allostery in drug design, putting together a whole array of technologies to identify and characterize allosteric modulators of protein function that will be applied to therapeutically relevant systems. Our approach is based on a combination of experimental and simulation techniques, including fragment Screening with structural characterization (X-ray, NMR, H/D exchange), proteomics (MS/MS), ITC, DNA encoding libraries, Virtual Screening, Molecular Dynamics simulations-based methods, Synthetic Chemistry, and in vitro and cellular assays for the verification of results. It should also be noted that allosteric targeting need not be achieved solely through the design of synthetic small molecules but also can also be reached via conformationally specific allosteric antibodies, which represents an important field of future research. There are already clear examples of monoclonal antibodies that allosterically target ion channels (Lee et al., 2014b), GPCRs (Mukund et al., 2013), and RTKs (De Smet et al., 2014), as well as cytokine and integrin receptors (Rizk et al., 2015; Schwarz et al., 2006).
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 252 788 € |
| FORSCHUNGSVERBUND BERLIN e. V. | 252 788 € |
| FORSCHUNGSZENTRUM JULICH GmbH | 252 788 € |
| HUN-REN Termeszettudomanyi Kutatokozpont | 229 715 € |
| Idryma Iatroviologikon Ereunon Akademias Athinon | 243 018 € |
| Janssen Pharmaceutica N.V. | 256 320 € |
| Karolinska Institutet | 281 983 € |
| MERCK HEALTHCARE KGaA | 252 788 € |
| Nxera Pharma UK Ltd. | 303 173 € |
| The University of Birmingham | 0,00 € |
| Universita' degli Studi di Urbino Carlo Bo | 261 500 € |
| Universitat de Barcelona | 501 810 € |
| Universitat Wien | 264 207 € |
| Universite de Strasbourg | 274 802 € |
https://cordis.europa.eu/project/id/956314
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "CHARITE - UNIVERSITAETSMEDIZIN BERLIN - Financement de l’UE (3 627 681 €) : L’allostérie dans la découverte de médicaments"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
